Therillume

Therillume email format

Verified email-pattern data for Therillume is currently limited. You can still use the company insights and contact sections below.
Therillume (“TLM” or the “Company”) is a clinical-stage neuro-oncology therapeutics company with an initial focus on glioblastoma (GBM) and Neurofibromatosis Type 1 and 2 (“NF1 and NF2”). Therillume is a human therapeutic spinout company from Recombinetics Inc. (“RCI”), leveraging its pioneering precise gene-editing platform to identify, validate and expedite high quality candidates through clinical development. In addition, Therillume is amassing a powerful consortium of KOL’s and leading institutions to advance novel and innovative therapies in neuro-oncology. The Company expects to enter the clinic in 2022 with therapies that have demonstrated safety and efficacy in human cancer clinical trials. Therillume is currently seeking Seed and Series A financing and strategic partners.

Company Details

Employees
1
Founded
-
Address
3388 Mike Collins Dr, Eagan,minnesota 55121,united States
Industry
Pharmaceutical Manufacturing
HQ
Eagan, Minnesota
Looking for a particular Therillume employee's phone or email?

Therillume Questions

Explore related pages

Related company profiles:

Top Therillume Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant